Jassem Jacek, Jassem Ewa, Jakóbkiewicz-Banecka Joanna, Rzyman Witold, Badzio Andrzej, Dziadziuszko Rafał, Kobierska-Gulida Grazyna, Szymanowska Amelia, Skrzypski Marcin, Zylicz Maciej
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Cancer. 2004 May 1;100(9):1951-60. doi: 10.1002/cncr.20191.
The objective of the current study was to determine whether tumor cells harboring P53 and K-ras mutations could be detected in histopathologically tumor-free surgical margins in patients with nonsmall cell lung carcinoma who underwent complete pulmonary resection.
In 118 consecutive patients, DNA obtained from primary tumors and from surgical margins was extracted for molecular analysis. A fragment of P53 gene encompassing exons 5-8 and codon 12 of the K-ras gene were amplified with the polymerase chain reaction technique and were assayed for the presence of mutations.
P53 and K-ras mutations were found in 30% and 39% of primary tumors, respectively, and in 11 (9%) and 22 (18%) apparently tumor-free surgical margins, respectively. At least 1 of those mutations was found in surgical margins in 29 patients (25%), and both mutations were found in 2 patients (1.7%). P53 mutations in surgical margins accompanied mutations in primary tumors in 9 of 35 patients (26%), and K-ras mutations accompanied mutations in primary tumors in 20 of 46 patients (44%). Among patients with either mutation in primary tumors, the incidence of at least 1 mutation in surgical margins was 43% (28 of 65 patients). In four patients, mutations (two K-ras mutations and two P53 mutations) were found in surgical margins despite the absence of the corresponding mutations in primary tumors. The presence of mutations in primary tumors and in surgical margins was not related significantly to clinical characteristics or to patient outcomes.
P53 and K-ras mutations are frequent events in surgical margins determined to be tumor free on light microscopy. The clinical relevance of these findings remains to be established.
本研究的目的是确定在接受全肺切除术的非小细胞肺癌患者中,组织病理学检查无肿瘤的手术切缘中是否能检测到携带P53和K-ras基因突变的肿瘤细胞。
对118例连续患者,提取原发肿瘤和手术切缘的DNA进行分子分析。用聚合酶链反应技术扩增P53基因包含外显子5-8的片段和K-ras基因的第12密码子,并检测是否存在突变。
分别在30%的原发肿瘤和39%的原发肿瘤中发现P53和K-ras基因突变,在分别11例(9%)和22例(18%)看似无肿瘤的手术切缘中也发现了这些突变。29例患者(25%)的手术切缘中至少发现了其中一种突变,2例患者(1.7%)的手术切缘中发现了两种突变。35例患者中有9例(26%)手术切缘中的P53突变与原发肿瘤中的突变同时出现,46例患者中有20例(44%)手术切缘中的K-ras突变与原发肿瘤中的突变同时出现。在原发肿瘤有任何一种突变的患者中,手术切缘中至少有1种突变的发生率为43%(65例患者中的28例)。4例患者的手术切缘中发现了突变(2例K-ras突变和2例P53突变),尽管原发肿瘤中没有相应的突变。原发肿瘤和手术切缘中突变的存在与临床特征或患者预后无显著相关性。
在光镜下确定为无肿瘤的手术切缘中,P53和K-ras基因突变很常见。这些发现的临床意义仍有待确定。